Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

NCT07741643 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT07741643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07741643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
July 31, 2031
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck surgery, hnscc,larynx, pharynx and oral cavity, squamous cell carcinoma